News | September 20, 2021
U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Subscribe To Our Newsletter & Stay Updated
